Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | SGMS2 | Q8NHU3 | 6/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 8/20 | 0.46 |
| ▸ | SGMS1 | Q86VZ5 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14805001 | 0.91 | EPHX2 (0.55) | EPHX2SGMS2GRM4SGMS1CYP1A2 | |
| SCHEMBL6923327 | 0.91 | EPHX2 (0.69) | EPHX2SGMS2GRM4SGMS1SYK | |
| SCHEMBL14804998 | 0.89 | EPHX2 (0.57) | EPHX2SGMS2GRM4SGMS1CYP1A2 | |
| SCHEMBL2234534 | 0.84 | GRM4 (0.61) | EPHX2SGMS2GRM4 | |
| SCHEMBL2235274 | 0.80 | EPHX2 (0.74) | EPHX2GRM4CYP1A2CTSC | |
| SCHEMBL14804990 | 0.80 | GRM4 (0.51) | EPHX2SGMS2GRM4SGMS1CYP1A2 | |
| SCHEMBL6922905 | 0.78 | EPHX2 (0.60) | EPHX2SGMS2GRM4SGMS1 | |
| SCHEMBL14804989 | 0.78 | EPHX2 (0.64) | EPHX2GRM4CYP1A2 | |
| SCHEMBL2235375 | 0.76 | GRM4 (0.58) | EPHX2SGMS2GRM4SGMS1SYK | |
| SCHEMBL14804987 | 0.75 | GRM4 (0.56) | EPHX2SGMS2GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916584-B2 | Benzisoxazoles and azabenzisoxazoles as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2011100614-A1 | BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079366-A1 | Benzisoxazoles and Azabenzisoxazoles as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRIK4, GRM4, GRIA4 | EPHX2 2498/4885SGMS2 2079/4885GRM4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.